Immunotherapy plus chemotherapy before surgery for cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have a specific type of cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) that has not spread to the pelvic wall or lower vagina.
- You have not had any prior treatment for cervical cancer (like chemotherapy or radiation).
- You are able to have surgery to remove your cervix and uterus (radical hysterectomy), and you agree to this surgery.
- You have at least one tumor that can be measured on imaging scans, and you are willing to provide tumor tissue and blood samples for research.
- Your overall health is good: your heart, liver, and kidney function are within acceptable limits, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a combination of an immunotherapy drug (QL1706) and two chemotherapy drugs (cisplatin and paclitaxel) before surgery for cervical cancer. The goal is to shrink the tumor to make surgery more effective and improve outcomes.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a new treatment that combines an immunotherapy drug (cadonilimab) with chemotherapy for people with locally advanced cervical cancer. The goal is to see if this combination can shrink the tumor enough to make surgery possible or more effective.
This trial tests if giving chemotherapy plus an immunotherapy drug before surgery can help shrink tumors and improve outcomes for patients with stage IB2 cervical cancer that has not been treated yet. It might be an option if you have a specific type of cervical cancer that shows a certain protein (PD-L1) on your tumor cells.
This trial tests a combination of three drugs before standard treatment for locally advanced cervical cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests a new combination of two immunotherapy drugs with standard chemotherapy before surgery for cervical cancer that has not spread far. The goal is to shrink the tumor and improve treatment outcomes.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.